Table 3:
O/E ratios, along with the 95% confidence intervals, for various prediction objectives of the CS and MPC models under two scenarios: (1) all validation subjects are included (No), and (2) only known and inferred mutation carriers and wildtypes are included (Yes).
| MPC model | |||
|---|---|---|---|
|
| |||
| Prediction objective | All validation subjects | O/E ratio | 95% CI |
| At least one cancer vs no cancer | No | 1.42 | 1.24 – 1.59 |
| At least one cancer vs no cancer (KM) | No | 0.65 | 0.57 – 0.72 |
| SPC vs MPC | No | 1.23 | 0.80 – 1.66 |
| At least one cancer vs no cancer | Yes | 1.59 | 1.42 – 1.75 |
| At least one cancer vs no cancer (KM) | Yes | 0.67 | 0.60 – 0.74 |
| SPC vs MPC | Yes | 1.26 | 0.84 – 1.68 |
|
| |||
| CS model | |||
|
| |||
| Prediction objective | All validation subjects | O/E ratio | 95% CI |
| Breast cancer vs all other outcomes | No | 1.51 | 1.16 – 1.85 |
| Sarcoma vs all other outcomes | No | 0.63 | 0.33 – 0.94 |
| Other cancers vs all other outcomes | No | 1.39 | 1.19 – 1.60 |
| Breast cancer vs all other outcomes | Yes | 1.75 | 1.40 – 2.09 |
| Sarcoma vs all other outcomes | Yes | 0.59 | 0.32 – 0.87 |
| Other cancers vs all other outcomes | Yes | 1.45 | 1.27 – 1.63 |